Skip to content

Remotely Observed Methadone Evaluation

Remotely Observed Methadone Evaluation (ROME)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06200740
Acronym
ROME
Enrollment
24
Registered
2024-01-11
Start date
2022-09-25
Completion date
2022-12-02
Last updated
2024-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Brief summary

Opioid addiction, which affects 16 million individuals worldwide, can be treated using methadone, a proven and effective opioid medication for treating OUD that extends retention in care, reduces mortality, and inhibits illicit drug use. However, methadone treatment is limited to federally certified Opioid Treatment Programs (OTPs), which must meet complex regulatory requirements, and require new patients to take their dose in person six days per week, presenting significant barriers to treatment. To address these barriers, Sonara Heath has developed the Sonara software platform, which will enable OTPs to offer accelerated take-home methadone regimens while maintaining safety and diversion prevention.

Interventions

DEVICESonara

web application facilitating asynchronous observation of methadone dosing

Sponsors

Oregon Health and Science University
CollaboratorOTHER
Stanford University
CollaboratorOTHER
Adapt Oregon
CollaboratorUNKNOWN
Sonara Health
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Receiving methadone for the treatment of opioid use disorder

Exclusion criteria

* Patients with \>13 take-homes * Patients with positive toxicology results in last 30-60 days * Patients involved with drug court ineligible for take-homes * Patients without adequate access to technology * Patients with \<30 days in treatment * Patients with mental health instability * Patients with recent diversion attempts * Patients using buprenorphine for agonist therapy * Patients guest dosing at another clinic during trial period

Design outcomes

Primary

MeasureTime frameDescription
System Usability Scale (SUS)two weeksThe SUS, a 10-item scale with each item rated on a 5-point scale (scored 0 to 4) with five negative statements (e.g., system is unnecessarily complex) (reverse scored) and five positive statements (e.g., system functions are well integrated), evaluated user perceptions of the system's usability. We summed scores and multiplied them by 2.5 for the total score with a range from 0 to 100 (Lewis, 2018).

Secondary

MeasureTime frameDescription
Acceptability, Appropriateness and Feasibility of Implementation Measurestwo weeksAcceptability Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) are single factor 4-item scales scored 1 to 5 and summed with test-retest reliabilities of 0.73 to 0.88 (Weiner et al., 2017). Scores for each of the three dimensions have a potential range of 4 to 20 with higher scores suggesting better implementation potential.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026